EUVIMEDEUVIMED entdecken
Metaanalyse

Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials

Thrombolyse beim ischämischen Schlaganfall jenseits des 4,5-Stunden-Fensters: Metaanalyse randomisierter klinischer Studien

Ahmet Günkan iD, Marcio Yuri Ferreira iD, Marina Vilardo iD, Luca Scarcia iD, Jhon E Bocanegra-Becerra iD, Leonardo Januario Campos Cardoso iD, Luis F Fabrini Paleare iD, Gustavo de Oliveira Almeida iD, Gabriel Semione iD, Christian Ferreira iD, Gabriele Ciccio iD, Adnan Mujanovic iD und 4 weitere

Stroke · 2025-03 · 56 (3) · 580-590

DOI: 10.1161/strokeaha.124.048536 ↗

Auf einen Blick

Acht RCTs zeigen jenseits von 4,5 Stunden nach Symptombeginn höhere Chancen auf gute funktionelle Ergebnisse unter IVT als unter Standardversorgung. Zugleich stieg die Rate symptomatischer intrazerebraler Blutungen.

Fragestellung

Verbessert intravenöse Thrombolyse bei ischämischem Schlaganfall nach 4,5 Stunden ohne mechanische Thrombektomie die funktionellen Ergebnisse im Vergleich zur Standardversorgung?

Methode

Systematische Suche in MEDLINE, Embase, Cochrane und ClinicalTrials.gov nach RCTs; Metaanalyse mit Random-Effects-Modell.

Ergebnisse

8 RCTs mit 1742 Patient:innen. Exzellentes Outcome: OR 1,43 (95 %-KI 1,17–1,75). Gutes Outcome: OR 1,36 (95 %-KI 1,12–1,66). sICH: OR 4,25 (95 %-KI 1,67–10,84). Mortalität nach 90 Tagen: OR 1,28 (95 %-KI 0,87–1,89).

Schlussfolgerung der Autor:innen

IVT jenseits von 4,5 Stunden führte ohne MT zu höheren Chancen auf exzellente und gute funktionelle Ergebnisse gegenüber Standardversorgung, bei höherer sICH-Rate und nicht signifikant erhöhter Mortalität.

Kernaussagen

  • Exzellentes Outcome häufiger unter IVT: OR 1,43 (95 %-KI 1,17–1,75)
  • sICH häufiger unter IVT: OR 4,25 (95 %-KI 1,67–10,84)
  • Mortalität nach 90 Tagen nicht signifikant verschieden

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Stroke, 2025-03. Verfasst von Ahmet Günkan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher (A.G.). Hauptthemen laut MEDLINE: Ischemic Stroke, Thrombolytic Therapy, Fibrinolytic Agents. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 25 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A minority of patients with stroke qualify for intravenous thrombolysis (IVT) within 4.5-hour window. The safety and efficacy of IVT beyond this period have not been well studied. METHODS: We systematically searched MEDLINE, Embase, Cochrane, and ClinicalTrials.gov for relevant randomized clinical trials. Randomized clinical trials comparing IVT versus standard medical care in patients with ischemic stroke beyond 4.5 hours of symptom onset or last known well without mechanical thrombectomy (MT) were included. Primary outcomes were excellent (modified Rankin Scale score of 0–1) and good (modified Rankin Scale score of 0–2) functional outcomes at 90 days, symptomatic intracerebral hemorrhage (sICH), and death at 90 days. Pooled odds ratios (ORs) with 95% CIs were calculated using a random-effects model. Heterogeneity was assessed by Q test and quantified by I ² values. RESULTS: Eight randomized clinical trials (1742 patients; mean age, 69.8±9 years, 63.5% men) were included. Compared with standard medical care, IVT achieved higher rates of excellent (OR, 1.43 [95% CI, 1.17–1.75]; Q =2.30; P =0.94; I 2 =0%) and good functional outcomes (OR, 1.36 [95% CI, 1.12–1.66]; Q =2.07; P =0.96; I 2 =0%) at 90 days but also increased sICH rates (OR, 4.25 [95% CI, 1.67–10.84], Q =0.48; P =0.99; I 2 =0%). Mortality at 90 days did not significantly differ between treatment groups (OR, 1.28 [95% CI, 0.87–1.89]; Q =4.63; P =0.59; I 2 =0%). Subanalyses yielded numerically higher odds of excellent functional outcomes when patients were selected with perfusion imaging (3 studies, OR, 1.45 [95% CI, 1.08–1.94]) compared with diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch (3 studies, OR, 1.34 [95% CI, 0.94–1.91]) and when treated with tenecteplase (3 studies, OR, 1.47 [95% CI, 1.06–2.04]) compared with alteplase (5 studies, OR, 1.38 [95% CI, 1.08–1.78]). CONCLUSIONS: IVT for ischemic stroke beyond 4.5 hours, without MT, led to increased odds of excellent and good functional outcomes compared with standard medical care, despite higher odds of sICH, and a nonsignificant numerical increase in mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeThrombolytic TherapyFibrinolytic AgentsHumansRandomized Controlled Trials as TopicTime-to-TreatmentTime FactorsMaleAgedTreatment OutcomeFemaleTissue Plasminogen Activator

Stichwörter der Autor:innen

alteplaseclinical trialshemorrhageischemic stroketenecteplasethrombectomythrombolysis

Substanzen

Fibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • Independent Researcher (A.G.).
  • Department of Neurosurgery, Lenox Hill Hospital/Northwell Health, New York, NY (M.Y.F., C.F., Y.S.).
  • School of Medicine, Catholic University of Brasilia (M.V.).
  • Department of Neuroradiology, Henri Mondor Hospital, Créteil, France (L.S.).
  • Academic Department of Surgery, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru (J.E.B.-B.).
  • Federal University of Minas Gerais, Belo Horizonte, Brazil (L.J.C.C.).

ORCID-Profile: Ahmet Günkan, Marcio Yuri Ferreira, Marina Vilardo, Luca Scarcia, Jhon E Bocanegra-Becerra, Leonardo Januario Campos Cardoso, Luis F Fabrini Paleare, Gustavo de Oliveira Almeida, Gabriel Semione, Christian Ferreira, Gabriele Ciccio, Adnan Mujanovic, Pascal Jabbour, Thanh N Nguyen, Jean-Claude Baron

Zitieren

APA

Günkan, A., Ferreira, M. Y., Vilardo, M., Scarcia, L., Bocanegra-Becerra, J. E., Cardoso, L. J. C., Fabrini Paleare, L. F., de Oliveira Almeida, G., Semione, G., Ferreira, C., Ciccio, G., Mujanovic, A., Jabbour, P., Serulle, Y., Nguyen, T. N., & Baron, J. C. (2025). Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials. Stroke, 56(3), 580-590. https://doi.org/10.1161/strokeaha.124.048536

Vancouver

Günkan A, Ferreira MY, Vilardo M, Scarcia L, Bocanegra-Becerra JE, Cardoso LJC, et al. Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials. Stroke. 2025;56(3):580-590. doi:10.1161/strokeaha.124.048536

BibTeX
@article{Gnkan2025,
  author = {Günkan, Ahmet and Ferreira, Marcio Yuri and Vilardo, Marina and Scarcia, Luca and Bocanegra-Becerra, Jhon E and Cardoso, Leonardo Januario Campos and Fabrini Paleare, Luis F and de Oliveira Almeida, Gustavo and Semione, Gabriel and Ferreira, Christian and Ciccio, Gabriele and Mujanovic, Adnan and Jabbour, Pascal and Serulle, Yafell and Nguyen, Thanh N and Baron, Jean-Claude},
  title = {Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {3},
  pages = {580--590},
  doi = {10.1161/strokeaha.124.048536}
}
Kostenlos starten →